Revealing S. Korean studies show antibodies could thwart COVID-19 reinfection, spread

Results from two new South Korean studies shed light on whether antibodies will be a reliable form of protection against COVID-19 for those who have recovered from the disease.

In one ongoing study, the Korean Center for Disease Control found that 100% of 25 randomly selected patients who were hospitalized with symptoms and who fully recovered, developed defensive antibodies against COVID-19.

Researchers were initially concerned that antibodies might not kill the virus, because roughly half of patients had both antibodies and a current COVID-19 infection.

Further investigation, however, suggested that the virus scientists detected might have been dead or so weak that it couldn't infect others.

In a second study of more than 10,700 COVID-19 patients, researchers examined 207 individuals who were re-diagnosed with COVID-19 after recovering from their infections.

In 39 of those 207 re-diagnosed individuals, researchers did not find any virus replication in patient samples they analyzed.

Editor’s Picks

Coronavirus map: Tracking the spread in the US and around the world

Front-line COVID doctor: We want student loan forgiveness, not hazard pay

Timeline: How coronavirus got started

In other words, the new research suggests that if a patient is re-diagnosed with COVID-19 after recovering, it's unlikely he or she will be able to infect others.

Still, the KCDC cautioned, it's unclear how long those antibodies last. Until we have that key piece of data, the jury is still out on whether mass immunity is possible.

ABC News' Joohee Cho contributed to this report.

What to know about the coronavirus:

• How it started and how to protect yourself: Coronavirus explained
• What to do if you have symptoms: Coronavirus symptoms
• Tracking the spread in the U.S. and worldwide: Coronavirus map

Tune into ABC at 1 p.m. ET and ABC News Live at 4 p.m. ET every weekday for special coverage of the novel coronavirus with the full ABC News team, including the latest news, context and analysis.